ADAP:NSD-Adaptimmune Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.61

Change

0.00 (0.00)%

Market Cap

USD 0.71B

Volume

1.29M

Average Target Price

USD 14.00 (+203.69%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.24B 20.76 16.02
MRNA Moderna, Inc

N/A

USD43.20B N/A N/A
SGEN Seagen Inc

N/A

USD29.62B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

N/A

USD26.98B 28.36 26.40
RPRX Royalty Pharma plc

N/A

USD25.62B 22.60 9.61
BGNE BeiGene, Ltd

N/A

USD25.22B N/A N/A
BNTX BioNTech SE

N/A

USD24.53B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ADAP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 284.17% 95% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 284.17% 95% A 96% A
Trailing 12 Months  
Capital Gain 382.72% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 382.72% 95% A 97% A+
Trailing 5 Years  
Capital Gain -49.34% 43% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.34% 43% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 15.73% N/A N/A 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.73% N/A N/A 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 106.41% N/A N/A 8% F
Risk Adjusted Return 14.78% N/A N/A 42% F
Market Capitalization 0.71B 70% C- 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.94 79% C+ 56% F
Price / Cash Flow Ratio -6.34 51% F 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -46.90% 63% D 23% F
Return on Invested Capital -75.58% 39% F 13% F
Return on Assets -22.96% 58% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.45 74% C 72% C-
Short Percent N/A N/A N/A N/A N/A
Beta 2.48 11% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector